TheStreet Downgrades Avanos Medical (AVNS) to C

Avanos Medical (NYSE:AVNS) was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating in a report released on Wednesday.

Several other research analysts also recently weighed in on AVNS. Zacks Investment Research downgraded Avanos Medical from a “hold” rating to a “sell” rating in a research note on Wednesday. Morgan Stanley increased their price target on Avanos Medical from $60.00 to $62.00 and gave the stock an “underweight” rating in a research note on Thursday, October 11th. KeyCorp increased their price target on Avanos Medical from $66.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. Barclays began coverage on Avanos Medical in a research note on Monday, October 15th. They set an “equal weight” rating and a $69.00 price target for the company. Finally, Raymond James upgraded Avanos Medical from a “market perform” rating to an “outperform” rating in a research note on Tuesday, August 21st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $69.25.

Shares of AVNS stock traded up $0.02 on Wednesday, hitting $50.63. 16,911 shares of the stock were exchanged, compared to its average volume of 330,049. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.18 and a current ratio of 2.78. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 21.56 and a beta of 1.86. Avanos Medical has a one year low of $43.78 and a one year high of $72.96.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.09. The company had revenue of $165.10 million during the quarter, compared to the consensus estimate of $166.57 million. Avanos Medical had a return on equity of 6.59% and a net margin of 14.26%. The business’s revenue was up 9.7% compared to the same quarter last year. Equities analysts predict that Avanos Medical will post 1.86 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bollard Group LLC purchased a new stake in shares of Avanos Medical in the 3rd quarter valued at about $100,000. Whittier Trust Co. purchased a new stake in shares of Avanos Medical in the 3rd quarter valued at about $110,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Avanos Medical in the 2nd quarter valued at about $136,000. CENTRAL TRUST Co purchased a new stake in shares of Avanos Medical in the 3rd quarter valued at about $167,000. Finally, Bank of Montreal Can purchased a new stake in shares of Avanos Medical in the 3rd quarter valued at about $197,000. 84.10% of the stock is currently owned by institutional investors and hedge funds.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Featured Story: How Important is Technical Analysis of Stocks

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply